Menorrhagia: Clinical Trials

44 trials for Menorrhagia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 5 terminated, 4 unknown, 2 recruiting. 44 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 344Completed 32, Terminated 5, Unknown 4, Recruiting 2, Withdrawn 1

Follow Menorrhagia: new trials by email Literature Review of Menorrhagia trials Research Report on Menorrhagia

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
KLH-2109+ Leurprorelin acetate Placebo, KLH-2109 Placebo + Leurprorelin acetate - Menorrhagia, Uterine Fibroids
Phase 3RecruitingJW Pharmaceutical2542026-02-032026-05-01
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Relugolix, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroids
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.1202024-01-152026-02-02
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
BG2109, Placebo for BG2109, Placebo for add-back therapy - Uterine Fibroids, Heavy Menstrual Bleeding
Phase 3UnknownBio Genuine (Shanghai) Biotech Co., Ltd.3122022-12-162023-03-21
Minimize Menorrhagia in Women With Von Willebrand Disease
recombinant von Willebrand factor, tranexamic acid - Von Willebrand Diseases
Phase 3TerminatedMargaret Ragni392019-02-072024-07-01
Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Levonorgestrel 52 mg intrauterine system - Menorrhagia
Phase 3CompletedMedicines3601052019-01-172024-05-14
Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss
Librata - Menorrhagia, Heavy Menstrual Bleeding
Phase 3UnknownLiNA Medical2002019-01-012018-11-07
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix - Uterine Leiomyoma, Uterine Fibroids
Phase 3CompletedMyovant Sciences GmbH2292018-10-162024-06-25
A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
Vilaprisan (BAY1002670) - Uterine Fibroids and Heavy Menstrual Bleeding
Phase 3TerminatedBayer1532018-03-302022-07-08
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Vilaprisan (BAY1002670), Placebo - Uterine Fibroids
Phase 3TerminatedBayer1032018-01-242022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Vilaprisan (BAY1002670), Placebo - Uterine Fibroids
Phase 3TerminatedBayer932018-01-172023-05-03
Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause
combined contraceptive pills (microcept), medroxyprogesterone acetate (progest), mefenamic acid (ponstan forte) - Improve Quality of Life, Heavy Menstrual Bleeding
Phase 3CompletedAssiut University2402017-11-012021-06-04
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Relugolix, Estradiol/norethindrone acetate - Heavy Menstrual Bleeding, Uterine Fibroid
Phase 3CompletedMyovant Sciences GmbH4772017-10-192024-05-09
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo - Heavy Menstrual Bleeding, Uterine Fibroids
Phase 3CompletedAbbVie4782017-09-132025-07-22
Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss
Tranexamic Acid 500 MG, Calcium Dobesilate - Menorrhagia
Phase 3UnknownAssiut University1402017-07-012018-06-27
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroid
Phase 3CompletedMyovant Sciences GmbH3822017-06-142022-04-20
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding
Phase 3CompletedObsEva SA5112017-05-232021-03-05
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo - Heavy Menstrual Bleeding, Uterine Fibroid
Phase 3CompletedMyovant Sciences GmbH3882017-04-262022-04-19
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding
Phase 3CompletedObsEva SA5262017-04-202021-06-09
Mirena Extension Trial
Levonorgestrel IUS (Mirena, BAY86-5028) - Contraception
Phase 3CompletedBayer3642016-12-222022-04-28
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Estradiol/Norethindrone Acetate, Elagolix - Uterine Fibroids, Heavy Menstrual Bleeding
Phase 3CompletedAbbVie4332016-09-142021-07-13

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Leiomyoma (23)  ·  Metrorrhagia (8)  ·  Uterine Hemorrhage (7)  ·  Anemia (1)  ·  Myofibroma (1)  ·  Uterine Neoplasms (1)  ·  von Willebrand Diseases (1)

Broader conditions

Female Urogenital Diseases (44)  ·  Female Urogenital Diseases and Pregnancy Complications (44)  ·  Genital Diseases (44)  ·  Genital Diseases, Female (44)  ·  Hemorrhage (44)  ·  Menstruation Disturbances (44)  ·  Pathologic Processes (44)  ·  Pathological Conditions, Signs and Symptoms (44)  ·  Urogenital Diseases (44)  ·  Uterine Diseases (44)  ·  Uterine Hemorrhage (37)  ·  Neoplasms (23)  ·  Neoplasms by Histologic Type (23)  ·  Neoplasms, Connective and Soft Tissue (23)  ·  Neoplasms, Muscle Tissue (23)

Interventions

estradiol, norethindrone drug combination (7)  ·  Tranexamic Acid (6)  ·  asoprisnil (6)  ·  Estradiol (5)  ·  Levonorgestrel (5)  ·  relugolix (5)  ·  Medroxyprogesterone Acetate (4)  ·  elagolix (4)  ·  Hysterectomy (3)  ·  Norethindrone Acetate (3)  ·  vilaprisan (3)  ·  linzagolix (2)  ·  Calcium Dobesilate (1)  ·  Endometrial Ablation Techniques (1)  ·  Iron (1)

Sponsors

Abbott (6)  ·  Bayer (6)  ·  AbbVie (4)  ·  Ferring Pharmaceuticals (4)  ·  Myovant Sciences GmbH (4)  ·  Assiut University (2)  ·  ObsEva SA (2)  ·  Aegea Medical, Inc. (1)  ·  Agency for Healthcare Research and Quality (AHRQ) (1)  ·  American Regent, Inc. (1)  ·  Bio Genuine (Shanghai) Biotech Co., Ltd. (1)  ·  Ethicon, Inc. (1)  ·  Guy Waddell (1)  ·  JW Pharmaceutical (1)  ·  LiNA Medical (1)

Countries

United States (22)  ·  Canada (7)  ·  Czechia (6)  ·  Brazil (5)  ·  Poland (5)  ·  South Africa (5)  ·  China (4)  ·  Hungary (4)  ·  Chile (3)  ·  Italy (3)  ·  Puerto Rico (3)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Egypt (2)  ·  Israel (2)

Top investigators

ObsEva SA (2)  ·  Andrea Olariu, MD, PhD (1)  ·  Anita Harding, MBChB (1)  ·  Charles T Cash, MD (1)  ·  Claude Fortin, MD (1)  ·  Congjian Xu (1)  ·  J.A. Reekers, MD, PhD (1)  ·  Jeong Yeol Park (1)  ·  Jorma Paavonen, prof (1)

Results publications

PMID 34878624, PMID 36357960, PMID 37477173, PMID 37863160, PMID 21043553, PMID 23188490, PMID 30865281, PMID 31971678, PMID 33596357, PMID 33650259, PMID 34553161, PMID 34582715, PMID 35415708, PMID 35675604, PMID 36116480, PMID 37183454, PMID 39381651, PMID 39466126, PMID 40326221, PMID 40543832, PMID 15547547, PMID 16880310, PMID 17671809, PMID 18055721, PMID 18567277, PMID 18752459, PMID 19111789, PMID 19682342, PMID 20733445, PMID 20859150, PMID 20942615, PMID 21475963, PMID 21777897, PMID 21867401, PMID 22748952, PMID 22959906, PMID 31777761, PMID 32702363, PMID 33603496, PMID 37023455, PMID 37385272, PMID 37437885, PMID 37666383, PMID 40320117, PMID 41059527

NIH funding

2016 (3), 2017 (2), 2018 (1), U01HL133815 (1)